NCCN Awards Grants to Investigators to Study Trifluridine & Tipiracil

P&T Community reports that the National Comprehensive Cancer Network (NCCN) Oncology Research Program has awarded grants to three clinical investigators from NCCN member institutions through a collaborative scientific research relationship with Taiho Oncology, Inc. to study the clinical effectiveness and safety of trifluridine and tipiracil (TAS-102) for treatment of various advanced, solid tumors. The investigators include:

  • Patrick Boland, MD Rosewell Park Comprehensive Cancer Center, a Phase II Study of TAS-102 Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)
  • Amit Mahipal, MBBSMayo Clinic Cancer CenterPhase II Trial of trifluridine/tipiracil in Combination with Irinotecan in Biliary Tract Cancers
  • Sarbajit Mukherjee, MD, MS, Roswell Park Comprehensive Cancer Center, Use of Trifluridine/tipiracil and Oxaliplatin as Induction Chemotherapy in Respectable Esophageal and Gastroesophageal junction (GEJ) Adenocarcinoma

What is TAS-102?

Approved by the FDA in 2015 and EMA in 2016, trifluridine/tipiracil (trade name Lonsurf) is a combination drug that is approved for use as a third- or fourth-line treatment of metastatic colorectal cancer, after chemotherapy and targeted therapeutics have failed. It is a combination of two active pharmaceutical ingredientstrifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor. Tipiracil prevents rapid metabolism of trifluridine, increasing the bioavailability of trifluridine.  It is used as a third or fourth-line treatment for metastatic colorectal cancer after chemotherapy and biologic therapy. Pregnant women should not take it.

Taiho Oncology Background

Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in TokyoJapan. Taiho is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Taiho is Japan’s second-largest pharmaceutical company by prescription oral oncology sales. The company mainly covers the oncology related therapeutic area: stomach cancer, colorectal cancer, pancreatic cancer, breast cancer and more. Taiho engages in research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Taiho is a full member of the Japan Pharmaceutical Manufacturers Association (JPMA).

Taiho has over 2,500 employees worldwide and achieved $1.1 billion USD according to financial reports

National Comprehensive Cancer Network (NCCN)

NCCN represents an alliance of 28 cancer centers in the United States—most of them are designated by the National Cancer Institute (one of the U.S. National Institute’s of Health) as comprehensive cancer centers.  


Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA; Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope National Medical Center, Duarte, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Rogel Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN.